GENETIC TECHNOLOGIES LIMITED — Capital/Financing Update 2024

Aug 1, 2024

ASX Market Announcement

==> picture [93 x 59] intentionally omitted <==

Lodgement of Prospectus

Melbourne Australia, August 2, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, following on from its announcement on 26 July 2024, is pleased to announce lodgment today of a prospectus for a 2 for 3 rights issue at 4 cents and 2 year term (with any fractions of a new share resulting from calculation of the entitlements rounded up to the next whole number); with an attaching 1:1 Option (with an exercise price of 4 cents) - to raise a minimum of $2 million and up to a maximum of $3.88 million (upon placement of entitlements and any shortfall).

Highlights:

• Prospectus for Entitlement Offer lodged with ASX and ASIC today –the Prospectus will be accessible from the Company’s website at www.genetype.com/investor-centre

• Eligible Shareholders holding Shares may subscribe under the Entitlement Offer for 2 New Shares for every 3 Shares held as at the Record Date of 7.00 pm on 7 August 2024, which Entitlement Offer includes the issue to the subscribers of 1 New Option for every New Share issued under the Entitlement Offer (including 1 New Option for every New Share issued under any Shortfall) ( Offer ).

• The issue price for New Shares is $0.04 (4 cents) per New Share.

• There is a minimum subscription to be raised under this Prospectus before the Entitlement Offer can close, namely the $2 million ( Minimum Subscription Amount ).

• Eligible Shareholders may also subscribe for Additional Shares (and corresponding New Options) beyond their Entitlement on the basis that some other existing Shareholders will be either ineligible or may fail to fully take up their Entitlement ( Top-Up Offer ). This Top-Up Offer to apply for Additional Securities is restricted only to Eligible Shareholders.

• If there remains any Shortfall after allocation of Entitlements to Eligible Shareholders under the Entitlement Offer and Top-Up Offer and the application of the $500,000 in reduction of the Secured Loans, the Directors also reserve the right for up to 3 months after the close of the Entitlement Offer to place any Shortfall at the Board's discretion under this Prospectus but at a price no less than the Issue Price ( Shortfall Offer ).

Chairman Peter Rubinstein said: “The funds raised under this Entitlement Offer will be critical to enable our transition to a leaner capital light operating structure and provide important working capital to support growth in our profitable EasyDNA and AffinityDNA businesses and advance the commercialisation of geneType across new and existing U.S. sales channels.”

Timetable for Entitlement Offer: The following is an indicative timetable for the Entitlement Offer:

Event	Date
Capital Raising announcement	25 July 2024
Lodgement of Prospectus with ASIC and ASX	2 August 2024
Record Date	7 August 2024
Dispatch of letter advising of access to Prospectus, prospectus available online and Entitlement Ofer opens	12 August 2024
Entitlement Ofer closes	2 September2024
Allotment and issue of New Shares under Entitlement Ofer	10 September2024
Expected normal trading of New Shares under Entitlement Ofer	11 September 2024

The above d ates / times are indicative and subject to change. All times / dates are in reference to Melbourne Time

The Company remains determined in our vision to be a leader in personalised preventative genomics, drive commercialisation of our innovation in genetic testing and expand our global footprint, delivering sustained value to our shareholders and stakeholders.

- END –

Authorised for release by the Board of Directors.

For investor inquiries, contact: Peter Rubinstein T: +613 8412 7000

E: investors@genetype.com

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

About EasyDNA

EasyDNA is an online marketplace established in 2007 in Malta and 2008 in Australia developing an online network of over 70 websites in over 40 countries. EasyDNA’s network of online retail sales platforms offers fast and affordable home DNA testing that is reliable and confidential. They also offer a number of lifestyle and health and wellbeing tests, and animal testing relating to allergies and tolerances. EasyDNA is a pioneering provider of genetic testing services, dedicated to delivering accurate and confidential results to individuals and organizations worldwide.

Forward Looking Statements

This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forwardlooking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forwardlooking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

==> picture [302 x 302] intentionally omitted <==